FUNDC2P2

Across TCGA pan-cancer cohorts, FUNDC2P2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FUNDC2P2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FUNDC2P2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FUNDC2P2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, ESCA, and SKCM are the cancer types where FUNDC2P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	1.000	0.498	.015	14	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
SKCM	DFS	Median	All	0.269	0.653	<.001	9	view →
SARC	OS	Median	All	0.241	0.766	.022	3	view →
GBM	OS	Median	All	0.167	0.414	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FUNDC2P2–BLCA (DFS)

Open the BLCA breakdown →